Emmaus Life Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
About Emmaus Life Sciences
Pharmaceutical Preparations, SIC 2834
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of treatments and therapies primarily involving pharmaceutical-grade L-glutamine. Its principal commercial product is Endari, which is marketed for patients with sickle cell disease. The company organizes its operations and product sales across domestic and international channels, serving healthcare distributors and medical providers across different markets.
The company conducts commercial activities domestically within the United States and internationally, including distribution operations and agreements involving partners across Japan and the United Arab Emirates. It maintains manufacturing and distribution partnerships with entities such as Telcon RF Pharmaceuticals. Emmaus Life Sciences, Inc. is incorporated in the State of Delaware, and its principal executive offices and corporate headquarters are located at 21250 Hawthorne Boulevard, Suite 800, in Torrance, California.
Summary of the business section of Emmaus Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Emmaus Life Sciences, Inc.
- Headquarters
- Torrance, CA
- Address
- 21250 Hawthorne Boulevard, Suite 800 90503
- Phone
- (310) 214-0065
- Website
- emmausmedical.com
- Employees
- 33, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Costa Mesa, CA
Stock & identifiers
- Ticker
- EMMA
- Exchange
- OTC
- Shares outstanding
- 70M, Aug 11, 2026
- Public float
- $581.66K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Jul 18, 2019; 1-for-200 reverse, Dec 22, 2016; 1-for-200 reverse, Sep 21, 2016; 1-for-30 reverse, May 15, 2012; 1-for-30 reverse, Apr 3, 2012
- SEC CIK
- 822370
- EIN
- 87-0419387
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Willis C. Lee | CEO, Director | 1,326,485 |
| Henry Huy Du | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 33 employees globally, 32 of whom were full-time.”
Corporate history
Events identified from SEC filings